Paul Ehrlich's passion: the origins of his receptor immunology - PubMed (original) (raw)
. 1999 Jun 15;194(2):213-21.
doi: 10.1006/cimm.1999.1505.
Affiliations
- PMID: 10383824
- DOI: 10.1006/cimm.1999.1505
Free article
Paul Ehrlich's passion: the origins of his receptor immunology
A M Silverstein. Cell Immunol. 1999.
Free article
Abstract
In 1897, Paul Ehrlich published a selection theory of antibody formation that anticipated the theories of Jerne and Burnet by some 60 years. Ehrlich introduced into immunology the concept of the interaction of physiologically active substances with specific receptors, an idea that still dominates modern immunological thought. In this paper, we point out how Ehrlich's concept matured over 20 years, while it governed his studies in histological staining, in cell physiology, in hematology, and finally in his major contributions in experimental immunology.
Copyright 1999 Academic Press.
Similar articles
- [Paul Ehrlich's concept of immune defense].
Doerr HW. Doerr HW. Dtsch Med Wochenschr. 1996 Jul 26;121(30):958-61. doi: 10.1055/s-0029-1233819. Dtsch Med Wochenschr. 1996. PMID: 8765706 German. No abstract available. - Paul Ehrlich's 150th birthday.
Staiger C. Staiger C. Pharm Hist (Lond). 2004 Jun;34(2):31-2. Pharm Hist (Lond). 2004. PMID: 15307256 No abstract available. - Paul Ehrlich and the Early History of Granulocytes.
Kay AB. Kay AB. Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.MCHD-0032-2016. Microbiol Spectr. 2016. PMID: 27726791 Review. - [100 years of Dr. Ehrlich's magic bullet (1909-2009)].
García-Sánchez JE, García E, Merino ML. García-Sánchez JE, et al. Enferm Infecc Microbiol Clin. 2010 Oct;28(8):521-33. doi: 10.1016/j.eimc.2009.07.009. Epub 2010 Jan 25. Enferm Infecc Microbiol Clin. 2010. PMID: 20097455 Review. Spanish.
Cited by
- Gaston Ramon's Big Four.
Chippaux JP. Chippaux JP. Toxins (Basel). 2024 Jan 9;16(1):33. doi: 10.3390/toxins16010033. Toxins (Basel). 2024. PMID: 38251249 Free PMC article. - Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M, Arlen PM, Tsang KY. Fantini M, et al. Front Immunol. 2023 Nov 24;14:1275904. doi: 10.3389/fimmu.2023.1275904. eCollection 2023. Front Immunol. 2023. PMID: 38077389 Free PMC article. Review. - Antibody-Drug Conjugates in Uro-Oncology.
Sigorski D, Różanowski P, Iżycka-Świeszewska E, Wiktorska K. Sigorski D, et al. Target Oncol. 2022 May;17(3):203-221. doi: 10.1007/s11523-022-00872-3. Epub 2022 May 14. Target Oncol. 2022. PMID: 35567672 Review. - Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.
Hays EM, Duan W, Shigdar S. Hays EM, et al. Int J Mol Sci. 2017 Nov 30;18(12):2576. doi: 10.3390/ijms18122576. Int J Mol Sci. 2017. PMID: 29189740 Free PMC article. Review. - Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology.
Ferner RE, Aronson JK. Ferner RE, et al. Br J Clin Pharmacol. 2016 Jan;81(1):52-5. doi: 10.1111/bcp.12721. Epub 2015 Oct 22. Br J Clin Pharmacol. 2016. PMID: 26174880 Free PMC article. Review.